CHF Solutions To Exhibit at Upcoming Heart Failure Conferences
October 03 2019 - 8:30AM
CHF Solutions, Inc. (Nasdaq:CHFS) today announced that it will be
exhibiting at two Heart Failure conferences during October:
Mount Sinai Advanced Innovations in Heart
FailureNew York Academy of MedicineNew York CityOctober
10, 2019 For information or to attend, please visit:
http://www.msadvanced.com/
MedStar Heart Failure SummitHyatt Regency,
BethesdaBethesda, Md.October 12, 2019For information or to attend,
please visit:
https://medstar.cloud-cme.com/default.aspx?P=0&EID=5617
“We are excited to be participating in these two important
conferences hosted by leading medical experts in heart failure,”
said John Erb chairman and CEO. “Our participation and
financial support further demonstrate our commitment to promoting
high quality care for patients suffering from heart failure.”
About CHF SolutionsCHF Solutions, Inc.
(Nasdaq:CHFS) is a medical device company dedicated to changing the
lives of patients suffering from fluid overload through science,
collaboration, and innovative technology. The company is focused on
developing, manufacturing, and commercializing the Aquadex FlexFlow
system for ultrafiltration therapy. CHF Solutions is a Delaware
corporation headquartered in Minneapolis, Minnesota with wholly
owned subsidiaries in Australia and Ireland. The company has been
listed on the Nasdaq Capital Market since February 2012.
Forward-Looking StatementsCertain statements in
this release are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including
without limitation, statements regarding the company’s
participation in heart failure conferences. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercialization strategy, the
possibility that we may be unable to raise sufficient funds
necessary for our anticipated operations, our post-market clinical
data collection activities, benefits of our products to patients,
our expectations with respect to product development and
commercialization efforts, our ability to increase market and
physician acceptance of our products, potentially competitive
product offerings, intellectual property protection, our ability to
integrate acquired businesses, our expectations regarding
anticipated synergies with and benefits from acquired businesses,
and other risks and uncertainties described in our filings with
the SEC. Forward-looking statements speak only as of the date
when made. CHF Solutions does not assume any obligation
to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACTS:
INVESTORS: Claudia Napal Drayton Chief
Financial Officer CHF Solutions, Inc. 952-345-4205
ir@chf-solutions.com-or- Bret Shapiro Managing Partner CORE IR
516-222-2560 brets@coreir.com www.coreir.com
MEDIA Jules Abraham JQA Partners, Inc.
917-885-7378 jabraham@jqapartners.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024